Guardant Health, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Guardant Health invites stockholders to its 2026 Annual Meeting on June 17, 2026, reporting 33% revenue growth to $982 million in 2025.
NASDAQ
Guardant Health is holding a stockholder meeting to vote on the election of Class I directors, the ratification of Deloitte & Touche LLP as their independent auditor, and an advisory vote on executive compensation.
NASDAQ
Guardant Health achieved significant milestones in 2024, including FDA approval of Shield and a 31% revenue increase, setting a positive trajectory for 2025.
NASDAQ
Guardant Health, Inc. has scheduled its annual stockholder meeting for June 12, 2024, and is seeking votes on the election of directors, ratification of auditors, and executive compensation.
NASDAQ
Guardant Health's proxy statement details the agenda for the 2024 Annual Meeting of Stockholders and recaps a year of solid growth and strategic advancements in 2023.